Marksans Pharma (BOM:524404) E10: ₹5.79 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524404 Marksans Pharma Ltd BOM:524404
80 GF Score
Price ₹327.45
GF Value ₹252.01
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Marksans Pharma E10?

Marksans Pharma BOM:524404 +0.35% 80 E10 is ₹5.79 as of Jun. 2026. GuruFocus rates BOM:524404 with a GF Score™ of 80/100 and a GF Value™ of ₹252.01 (Modestly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Marksans Pharma's adjusted earnings per share data for the three months ended in Jun. 2026 was ₹3.470. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is ₹5.79 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Marksans Pharma's average E10 Growth Rate was 24.60% per year. During the past 3 years, the average E10 Growth Rate was 15.30% per year. During the past 5 years, the average E10 Growth Rate was 16.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Marksans Pharma was 19.80% per year. The lowest was 15.30% per year. And the median was 16.30% per year.

As of today (2026-08-19), Marksans Pharma's current stock price is ₹327.45. Marksans Pharma's E10 for the quarter that ended in Jun. 2026 was ₹5.79. Marksans Pharma's Shiller PE Ratio of today is 56.55.

During the past 13 years, the highest Shiller PE Ratio of Marksans Pharma was 78.97. The lowest was 7.25. And the median was 28.82.


Marksans Pharma  (BOM:524404) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Marksans Pharma's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=327.45/5.79
=56.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Marksans Pharma was 78.97. The lowest was 7.25. And the median was 28.82.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Marksans Pharma E10 Related Terms


Marksans Pharma E10 Historical Data

* Premium members only.

The historical data trend for Marksans Pharma's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Marksans Pharma E10 Chart

Marksans Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.90 3.51 4.03 4.56 5.39

Marksans Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.63 4.79 5.00 5.39 5.79

BOM:524404 vs LLY, JNJ, ABBV: E10 Comparison

For the Drug Manufacturers - General subindustry, Marksans Pharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Marksans Pharma Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Marksans Pharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Marksans Pharma's Shiller PE Ratio falls into.


BOM:524404
80GF Score
Marksans Pharma Ltd BOM:524404
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Marksans Pharma E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Marksans Pharma's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=3.47/167.3573*167.3573
=3.470

Current CPI (Jun. 2026) = 167.3573.

Marksans Pharma Quarterly Data

per share eps CPI Adj_EPS
201609 0.020 105.961 0.032
201612 0.240 105.196 0.382
201703 -0.150 105.196 -0.239
201706 0.330 107.109 0.516
201709 0.230 109.021 0.353
201712 0.410 109.404 0.627
201803 -0.170 109.786 -0.259
201806 0.580 111.317 0.872
201809 0.480 115.142 0.698
201812 0.600 115.142 0.872
201903 0.210 118.202 0.297
201906 0.520 120.880 0.720
201909 0.630 123.175 0.856
201912 0.710 126.235 0.941
202003 1.090 124.705 1.463
202006 1.200 127.000 1.581
202009 1.210 130.118 1.556
202012 1.420 130.889 1.816
202103 1.998 131.771 2.538
202106 1.510 134.084 1.885
202109 1.110 135.847 1.367
202112 1.200 138.161 1.454
202203 0.690 138.822 0.832
202206 1.460 142.347 1.717
202209 1.520 144.661 1.758
202212 1.560 145.763 1.791
202303 1.870 146.865 2.131
202306 1.520 150.280 1.693
202309 1.840 151.492 2.033
202312 1.840 152.924 2.014
202403 1.730 153.035 1.892
202406 1.960 155.789 2.106
202409 2.130 157.882 2.258
202412 2.310 158.323 2.442
202503 2.000 157.552 2.124
202506 1.290 159.755 1.351
202509 2.170 162.289 2.238
202512 2.500 163.281 2.562
202603 3.270 164.272 3.331
202606 3.470 167.357 3.470

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of ₹5.79 mean?
Marksans Pharma (BOM:524404) has a E10 of ₹5.79 as of Jun. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Marksans Pharma and its competitors.
Is Marksans Pharma's E10 too high?
Marksans Pharma's current E10 is ₹5.79. Overall, Marksans Pharma has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Marksans Pharma's E10 compare to LLY and JNJ?
Marksans Pharma's E10 of ₹5.79 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Marksans Pharma and its competitors. Marksans Pharma's current E10 is ₹5.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marksans Pharma stock overvalued right now?
Based on GuruFocus' analysis, Marksans Pharma (BOM:524404) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹252.01, compared to a current price of ₹327.45 — trading 29.9% above its estimated fair value. The current E10 is ₹5.79. Marksans Pharma's overall GF Score™ is 80/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Marksans Pharma (BOM:524404), the current E10 is ₹5.79 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Marksans Pharma (BOM:524404) Overvalued in 2026?

Based on GuruFocus' analysis, Marksans Pharma stock appears to be overvalued. The current stock price of ₹327.45 is trading 29.9% above its estimated GF Value™ of ₹252.01. GuruFocus considers Marksans Pharma to be Modestly Overvalued.

Key valuation signals for BOM:524404:

  • E10: ₹5.79
  • GF Value™: ₹252.01 vs. price of ₹327.45 (29.9% above fair value)
  • GF Score™: 80/100 with 7 warning signs

No single metric tells the full story. See the BOM:524404 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Marksans Pharma Business Description

Other Exchanges MARKSANS:India
Address Veera Desai Extension Road, 11th Floor, Grandeur, Opposite Gundecha Symphony, Oshiwara, Andheri (West), Mumbai, MH, IND, 400053
Marksans Pharma Ltd is a pharmaceutical company. The company is engaged in the research, manufacturing, and marketing of pharmaceutical formulations. It manufactures analgesics, gastroenterology, anti-diabetic, cardiovascular, pain management, gynecology, gastrointestinal, and oncologic drugs as well as antibiotics and antiallergic medications. Geographically, the majority of its revenue is generated from the United States and North America, followed by Europe and the UK, Australia and New Zealand, and the Rest of the World.
80GF Score

Get the complete analysis for BOM:524404

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹327.45
Price
₹252.01
GF Value